Published in AIDS Weekly, March 1st, 1999
Clinicians face this question for each patient responding to highly active antiretroviral therapy (HAART). When can such a patient cease taking medicines that prevent opportunistic infections (OIs)' And when should OI prophylaxis be reinstated' The answer must be based on data that only now is beginning to emerge from longitudinal studies.
"We can see that with discontinuation of prophylaxis risk seems to be diminishingly small for many opportunistic infections," said Constance Benson of the University of Colorado. "The challenge for clinicians is to identify those patients who can safely stop primary and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.